# Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

> **NCT00376883** · PHASE3 · COMPLETED · sponsor: **Nordic Myeloma Study Group** · enrollment: 500 (—)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** pamidronate

## Key facts

- **NCT ID:** NCT00376883
- **Lead sponsor:** Nordic Myeloma Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 500 (—)
- **Last updated:** 2007-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00376883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00376883, "Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00376883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*